UroGen Pharma Ltd. — Director's Dealing 2019

Jan 10, 2019

SEC Form 3 — Initial Statement of Beneficial Ownership

Issuer: UroGen Pharma Ltd. (URGN)
CIK: 0001668243
Period of Report: 2019-01-01

Reporting Person: PFREUNDSCHUH PETER P. (CFO)

Holdings (Non-Derivative)

Security	Shares	Ownership
Ordinary Shares	1000	Direct

Holdings (Derivative)

Security	Exercise Price	Expiration	Underlying	Shares	Ownership
Employee Stock Option (right to buy)	$42.23	2028-08-20	Ordinary Shares (50000)		Direct
Restricted Stock Unit	$		Ordinary Shares (12500)		Direct

Footnotes

F1: 33.33% of the shares underlying the stock option will vest on August 20, 2019 and 8.33% of the remaining shares will vest in equal quarterly installments thereafter.

F2: 33.33% of the restricted stock units ("RSUs") will vest on August 20, 2019 and 8.33% of the remaining RSUs vest in equal quarterly installments thereafter.

F3: Each RSU represents a contingent right to receive one share of the Issuer's common stock.